Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Scott J Antonia, Augusto Villegas, Davey Daniel...
https://pubmed.ncbi.nlm.nih.gov/28885881/Actively Recruiting
Led by Sun Yat-sen University · Updated on 2025-07-23
311
Participants Needed
3
Research Sites
N/A
Total Duration
Researchers are investigating treatments for locally advanced non-small cell lung cancer LANSCLC, focusing on comparing two radiotherapy approaches combined with immunotherapy. This phase III randomized controlled trial evaluates whether hypofractionated chemoradiotherapy followed by consolidative immunotherapy is as effective and safe as conventional fractionated chemoradiotherapy followed by consolidative immunotherapy in patients with this condition. Participants are randomly assigned in a 21 ratio to either receive hypofractionated chemoradiotherapy or conventional fractionated chemoradiotherapy. Both groups receive consolidative immunotherapy for up to 12 months after completing chemoradiotherapy. The hypofractionated group undergoes a split-course radiotherapy with specific dosing schedules and intervals, while the conventional group receives a standard fractionated radiotherapy dose. Concurrent chemotherapy with paclitaxel plus platinum-based or pemetrexed plus platinum-based agents is given during radiotherapy. Throughout the study, participants undergo assessments of tumor response, toxicity, and quality of life at defined intervals. Researchers monitor progression-free survival over two years as the primary outcome, along with secondary outcomes including response rate, overall survival, failure patterns, adverse events, and quality of life using specific questionnaires. Safety is closely observed for one year after treatment, and the total study duration extends up to the end date in 2029, with structured follow-ups and evaluations throughout.
CONDITIONS
Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC
B
Bo Qiu, Professor
H
Hui Liu, Professor
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Sun Yat-sen University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 6 weeks
Participants receive concurrent chemotherapy combined with either hypofractionated or conventional fractionated radiotherapy to treat locally advanced non-small cell lung cancer.
Daily visits for radiation therapy over 6 to 7 weeks with concurrent chemotherapy
Duration - Up to 12 months
Following chemoradiotherapy, participants receive PD-1/PD-L1 immune checkpoint inhibitor therapy for up to 12 months to consolidate treatment response.
Regular visits for immunotherapy administration and monitoring over 12 months
Duration - Up to 2 years
Participants undergo follow-up visits to monitor safety, disease progression, and quality of life after completion of consolidative immunotherapy.
Periodic visits over 2 years
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Scott J Antonia, Augusto Villegas, Davey Daniel...
https://pubmed.ncbi.nlm.nih.gov/28885881/Greg A Durm, Salma K Jabbour, Sandra K Althouse...
https://pubmed.ncbi.nlm.nih.gov/32697352/Rui Zhou, Bo Qiu, Mai Xiong...
https://pubmed.ncbi.nlm.nih.gov/37100160/Jhanelle E Gray, Augusto Villegas, Davey Daniel...
https://pubmed.ncbi.nlm.nih.gov/31622733/Youjin Lee, Sogyong L Auh, Yugang Wang...
https://pubmed.ncbi.nlm.nih.gov/19349616/Aaron T Wild, Joseph M Herman, Avani S Dholakia...
https://pubmed.ncbi.nlm.nih.gov/26867885/Alexander Filatenkov, Jeanette Baker, Antonia M S Mueller...
https://pubmed.ncbi.nlm.nih.gov/25869387/Chad Tang, Zhongxing Liao, Daniel Gomez...
https://pubmed.ncbi.nlm.nih.gov/25035212/Feng-Ming Kong, Randall K Ten Haken, Matthew Schipper...
https://pubmed.ncbi.nlm.nih.gov/28570742/David R Spigel, Corinne Faivre-Finn, Jhanelle E Gray...
https://pubmed.ncbi.nlm.nih.gov/35108059/Sun Yat-sen University
Lead Sponsor